An Investigational RNAi Therapeutic Targeting Factor XII (ALN-F12) for the Treatment of Hereditary Angioedema

Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2015.12.917
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

F12-Related Hereditary Angioedema With Normal C1Inh

2020English

Therapeutic Trial in Hereditary Angioedema Type III: Icatibant

World Allergy Organization Journal
ImmunologyPulmonaryAllergyRespiratory Medicine
2015English

Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema

New England Journal of Medicine
Medicine
2010English

The Hereditary Angioedema Syndromes

Journal of Clinical Investigation
Medicine
2018English

The Pathophysiology of Hereditary Angioedema

World Allergy Organization Journal
ImmunologyPulmonaryAllergyRespiratory Medicine
2010English

Treatment of Hereditary Angioedema With Plasma-Derived C1 Inhibitor

Therapeutics and Clinical Risk Management
2008English

Impact of Patisiran, an RNAi Therapeutic, on Orthostatic Intolerance in Patients With Hereditary Transthyretin-Mediated Amyloidosis

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Socioeconomic Burden of Hereditary Angioedema: Results From the Hereditary Angioedema Burden of Illness Study in Europe

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2014English

Hereditary Angioedema as a Metabolic Liver Disorder: Novel Therapeutic Options and Prospects for Cure

Frontiers in Immunology
AllergyImmunology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy